Search

Your search keyword '"Kies, Merrill"' showing total 702 results
Start Over Author "Kies, Merrill"
702 results on '"Kies, Merrill"'

1. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234

Author

Michikawa, Chieko, Torres-Saavedra, Pedro A, Silver, Natalie L, Harari, Paul M, Kies, Merrill S, Rosenthal, David I, Le, Quynh-Thu, Jordan, Richard C, Duose, Dzifa Y, Mallampati, Saradhi, Trivedi, Sanchit, Luthra, Rajyalakshmi, Wistuba, Ignacio I, Osman, Abdullah A, Lichtarge, Olivier, Foote, Robert L, Parvathaneni, Upendra, Hayes, D Neil, Pickering, Curtis R, and Myers, Jeffrey N

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Dental/Oral and Craniofacial Disease, Radiation Oncology, Rare Diseases, Clinical Trials and Supportive Activities, Orphan Drug, Digestive Diseases, 4.2 Evaluation of markers and technologies, 6.1 Pharmaceuticals, Detection, screening and diagnosis, Evaluation of treatments and therapeutic interventions, AMP Exception, Oncology and carcinogenesis
Abstract

PurposeAn evolutionary action scoring algorithm (EAp53) based on phylogenetic sequence variations stratifies patients with head and neck squamous cell carcinoma (HNSCC) bearing TP53 missense mutations as high-risk, associated with poor outcomes, or low-risk, with similar outcomes as TP53 wild-type, and has been validated as a reliable prognostic marker. We performed this study to further validate prior findings demonstrating that EAp53 is a prognostic marker for patients with locally advanced HNSCC and explored its predictive value for treatment outcomes to adjuvant bio-chemoradiotherapy.Methods and materialsEighty-one resection samples from patients treated surgically for stage III or IV human papillomavirus-negative HNSCC with high-risk pathologic features, who received either radiation therapy + cetuximab + cisplatin (cisplatin) or radiation therapy + cetuximab + docetaxel (docetaxel) as adjuvant treatment in a phase 2 study were subjected to TP53 targeted sequencing and EAp53 scoring to correlate with clinical outcomes. Due to the limited sample size, patients were combined into 2 EAp53 groups: (1) wild-type or low-risk; and (2) high-risk or other.ResultsAt a median follow-up of 9.8 years, there was a significant interaction between EAp53 group and treatment for overall survival (P = .008), disease-free survival (P = .05), and distant metastasis (DM; P = .004). In wild-type or low-risk group, the docetaxel arm showed significantly better overall survival (hazard ratio [HR] 0.11, [0.03-0.36]), disease-free survival (HR 0.24, [0.09-0.61]), and less DM (HR 0.04, [0.01-0.31]) than the cisplatin arm. In high-risk or other group, differences between treatments were not statistically significant.ConclusionsThe docetaxel arm was associated with better survival than the cisplatin arm for patients with wild-type or low-risk EAp53. These benefits appear to be largely driven by a reduction in DM.

Published
2022

2. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial

Author

Gold, Kathryn A, Kies, Merrill S, William, William N, Johnson, Faye M, Lee, J Jack, and Glisson, Bonnie S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Rare Diseases, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Disease Progression, ErbB Receptors, Erlotinib Hydrochloride, Feasibility Studies, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Protein Kinase Inhibitors, Response Evaluation Criteria in Solid Tumors, Skin Neoplasms, squamous cell carcinoma, skin cancer, erlotinib, epidermal growth factor receptor, anti-neoplastic agents, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BACKGROUND:Cutaneous squamous cell carcinoma (CSCC) is a very common malignancy in which most patients present with localized disease. Recurrent and metastatic disease is rare, and there is no standard therapy. These tumors frequently overexpress the epidermal growth factor receptor (EGFR). We conducted a phase 2 trial to determine the response rate to therapy with erlotinib, an EGFR tyrosine kinase inhibitor, in patients with locoregionally recurrent or metastatic CSCC that was not amenable to curative treatment (NCT01198028). METHODS:Eligible patients had CSCC not amenable to curative intent therapy. Patients who had previously received anti-EGFR targeted therapy were excluded. All patients received oral therapy with erlotinib 150 mg daily. Response was assessed every 8 weeks, and treatment continued until progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was overall response rate according to RECIST 1.1 criteria. RESULTS:A total of 39 patients received treatment during the trial; 29 of these patients were evaluable for response. The overall response rate was 10% (3/29); all responses were partial responses. The disease control rate (partial response + stable disease) was 72% (21/29). The median progression-free survival was 4.7 months (95% confidence interval, 3.5-6.2 months); the median overall survival was 13 months (95% confidence interval, 8.4-20.5 months). No unexpected toxicities were seen. CONCLUSION:Erlotinib therapy was feasible for most patients with incurable CSCC and was associated with expected toxicities. However, only a modest response rate of 10% was observed. Further study of EGFR tyrosine kinase inhibitors in this patient population is not warranted. Cancer 2018;124:2169-73. © 2018 American Cancer Society.

Published
2018

3. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

Author

Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R, Glisson, Bonnie S, Kies, Merrill S, Tsimberidou, Apostolia M, Wheler, Jennifer J, Zinner, Ralph G, Hong, David S, Kurzrock, Razelle, and Piha-Paul, Sarina A

Subjects
Rare Diseases, Clinical Research, Dental/Oral and Craniofacial Disease, Cancer, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Cetuximab, Female, Follow-Up Studies, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Prognosis, Sirolimus, Survival Rate, solid tumors, bevacizumab, cetuximab, temsirolimus, Oncology and Carcinogenesis
Abstract

BackgroundBevacizumab and temsirolimus are active agents in advanced solid tumors. Temsirolimus inhibits mTOR in the PI3 kinase/AKT/mTOR pathway as well as CYP2A, which may be a resistance mechanism for cetuximab. In addition, temsirolimus attenuates upregulation of HIF-1α levels, which may be a resistance mechanism for bevacizumab.Patients and methodsWe analyzed safety and responses in 21 patients with advanced solid tumors treated with bevacizumab, cetuximab, and temsirolimus.ResultsThe median age of patients was 60 years (range, 23-80 years). The median number of prior systemic therapies was 3 (range, 1-6). The maximum tolerated dose (MTD) was determined to be bevacizumab 10 mg/kg biweekly, temsirolimus 5 mg weekly and cetuximab 100/75 mg/m2 weekly. Grade 3 or 4 toxicities were seen in 52% of patients with the highest prevalence being hyperglycemia (14%) and hypophosphatemia (14%). Eighteen of the 21 patients were evaluable for response. Three patients were taken off the study before restaging for toxicities. Partial response (PR) was observed in 2/18 patients (11%) and stable disease (SD) lasting ≥ 6 months was observed in 4/18 patients (22%) (total = 6/18 (33%)). In 8 evaluable patients with squamous cell carcinoma of the head and neck (HNSCC) there were partial responses in 2/8 (25%) patients and SD ≥ 6 months in 1/8 (13%) patients (total = 3/8, (38%)).ConclusionThe combination of bevacizumab, cetuximab, and temsirolimus showed activity in HNSCC; however, there were numerous toxicities reported, which will require careful management for future clinical development.

Published
2016

4. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

Author

Tsimberidou, Apostolia Maria, Hong, David S., Fu, Siqing, Karp, Daniel D., Piha-Paul, Sarina, Kies, Merrill S., Ravi, Vinod, Subbiah, Vivek, Patel, Sunil M., Tu, Shi-Ming, Janku, Filip, Heymach, John, Johnson, Amber, Cartwright, Carrie, Zhao, Li, Zhang, Jianhua, Berry, Donald A., Vining, David J., Futreal, Andrew, Miller, Vincent A., and Meric-Bernstam, Funda

Published
2021
Full Text
View/download PDF

5. Head and Neck Cancers, Version 1.2015.

Author

Pfister, David G, Spencer, Sharon, Brizel, David M, Burtness, Barbara, Busse, Paul M, Caudell, Jimmy J, Cmelak, Anthony J, Colevas, A Dimitrios, Dunphy, Frank, Eisele, David W, Foote, Robert L, Gilbert, Jill, Gillison, Maura L, Haddad, Robert I, Haughey, Bruce H, Hicks, Wesley L, Hitchcock, Ying J, Jimeno, Antonio, Kies, Merrill S, Lydiatt, William M, Maghami, Ellie, McCaffrey, Thomas, Mell, Loren K, Mittal, Bharat B, Pinto, Harlan A, Ridge, John A, Rodriguez, Cristina P, Samant, Sandeep, Shah, Jatin P, Weber, Randal S, Wolf, Gregory T, Worden, Frank, Yom, Sue S, McMillian, Nicole, and Hughes, Miranda

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Dental/Oral and Craniofacial Disease, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Carbon, Guidelines as Topic, Head and Neck Neoplasms, Heavy Ion Radiotherapy, Humans, Neutron Capture Therapy, Proton Therapy, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.

Published
2015

7. Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications

Author

Mitani, Yoshitsugu, Rao, Pulivarthi H, Maity, Sankar N, Lee, Yu-Chen, Ferrarotto, Renata, Post, Julian C, Licitra, Lisa, Lippman, Scott M, Kies, Merrill S, Weber, Randal S, Caulin, Carlos, Lin, Sue-Hwa, and El-Naggar, Adel K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Genetics, Prostate Cancer, Urologic Diseases, Biotechnology, Aetiology, 2.1 Biological and endogenous factors, Adult, Aged, Aged, 80 and over, Alternative Splicing, Animals, Carcinoma, Ductal, Cell Line, Tumor, Disease Models, Animal, Female, Gene Dosage, Gene Expression, Heterografts, Humans, Male, Mice, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Protein Transport, Receptors, Androgen, Salivary Ducts, Salivary Gland Neoplasms, Transcriptional Activation, Tumor Burden, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeTo investigate the molecular events associated with the activation of androgen receptor (AR) as a potential therapeutic target in patients with salivary duct carcinoma (SDC).Experimental designComprehensive molecular and expression analysis of the AR gene in 35 tumor specimens (20 males and 15 females) and cell lines derived from SDC using Western blotting and RT-PCR, FISH analysis, and DNA sequencing was conducted. In vitro and in vivo animal studies were also performed.ResultsAR expression was detected in 70% of the tumors and was mainly nuclear and homogenous in both male and female SDCs, although variable cytoplasmic and/or nuclear localization was also found. We report the identification of ligand-independent AR splice variants, mutations, and extra AR gene copy in primary untreated SDC tumors. In contrast to prostate cancer, no AR gene amplification was observed. In vitro knockdown of AR in a female derived SDC cell line revealed marked growth inhibition in culture and in vivo androgen-independent tumor growth.ConclusionsOur study provides new detailed information on the molecular and structural alterations associated with AR gene activation in SDC and sheds more light on the putative functional role of AR in SDC cells. On the basis of these data, we propose that patients with SDC (male and female) can be stratified for hormone-based therapy in future clinical trials.

Published
2014

8. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Author

Pfister, David G, Spencer, Sharon, Brizel, David M, Burtness, Barbara, Busse, Paul M, Caudell, Jimmy J, Cmelak, Anthony J, Colevas, A Dimitrios, Dunphy, Frank, Eisele, David W, Gilbert, Jill, Gillison, Maura L, Haddad, Robert I, Haughey, Bruce H, Hicks, Wesley L, Hitchcock, Ying J, Jimeno, Antonio, Kies, Merrill S, Lydiatt, William M, Maghami, Ellie, Martins, Renato, McCaffrey, Thomas, Mell, Loren K, Mittal, Bharat B, Pinto, Harlan A, Ridge, John A, Rodriguez, Cristina P, Samant, Sandeep, Schuller, David E, Shah, Jatin P, Weber, Randal S, Wolf, Gregory T, Worden, Frank, Yom, Sue S, McMillian, Nicole R, Hughes, Miranda, and National Comprehensive Cancer Network

Subjects
National Comprehensive Cancer Network, Humans, Head and Neck Neoplasms, Neoplasm Staging, Combined Modality Therapy, Quality of Life, Oncology & Carcinogenesis
Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers focuses on glottic laryngeal cancer, which is the most common type of laryngeal cancer and has an excellent cure rate. The lymphatic drainage of the glottis is sparse, and early stage primaries rarely spread to regional nodes. Because hoarseness is an early symptom, most glottic laryngeal cancer is early stage at diagnosis. Updates to these guidelines for 2014 include revisions to "Principles of Radiation Therapy" for each site and "Principles of Surgery," and the addition of a new section on "Principles of Dental Evaluation and Management."

Published
2014

9. Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234

Author

Harari, Paul M, Harris, Jonathan, Kies, Merrill S, Myers, Jeffrey N, Jordan, Richard C, Gillison, Maura L, Foote, Robert L, Machtay, Mitchell, Rotman, Marvin, Khuntia, Deepak, Straube, William, Zhang, Qiang, and Ang, Kian

Subjects
Rare Diseases, Cancer, Clinical Trials and Supportive Activities, Dental/Oral and Craniofacial Disease, Clinical Research, 6.1 Pharmaceuticals, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Cetuximab, Chemoradiotherapy, Adjuvant, Cisplatin, Disease-Free Survival, Docetaxel, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Staging, Postoperative Care, Squamous Cell Carcinoma of Head and Neck, Survival Analysis, Taxoids, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo report results of a randomized phase II trial (Radiation Therapy Oncology Group RTOG-0234) examining concurrent chemoradiotherapy and cetuximab in the postoperative treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) with high-risk pathologic features.Patients and methodsEligibility required pathologic stage III to IV SCCHN with gross total resection showing positive margins and/or extracapsular nodal extension and/or two or more nodal metastases. Patients were randomly assigned to 60 Gy radiation with cetuximab once per week plus either cisplatin 30 mg/m(2) or docetaxel 15 mg/m(2) once per week.ResultsBetween April 2004 and December 2006, 238 patients were enrolled. With a median follow-up of 4.4 years, 2-year overall survival (OS) was 69% for the cisplatin arm and 79% for the docetaxel arm; 2-year disease-free survival (DFS) was 57% and 66%, respectively. Patients with p16-positive oropharynx tumors showed markedly improved survival outcome relative to patients with p16-negative oropharynx tumors. Grade 3 to 4 myelosuppression was observed in 28% of patients in the cisplatin arm and 14% in the docetaxel arm; mucositis was observed in 56% and 54%, respectively. DFS in this study was compared with that in the chemoradiotherapy arm of the RTOG-9501 trial (Phase III Intergroup Trial of Surgery Followed by Radiotherapy Versus Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head and Neck), which had a hazard ratio of 0.76 for the cisplatin arm versus control (P = .05) and 0.69 for the docetaxel arm versus control (P = .01), reflecting absolute improvement in 2-year DFS of 2.5% and 11.1%, respectively.ConclusionThe delivery of postoperative chemoradiotherapy and cetuximab to patients with SCCHN is feasible and tolerated with predictable toxicity. The docetaxel regimen shows favorable outcome with improved DFS and OS relative to historical controls and has commenced formal testing in a phase II/III trial.

Published
2014

10. Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in “Low-Intermediate Risk” Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy

Author

Goepfert, Ryan P., Lewin, Jan S., Barrow, Martha P., Gunn, G. Brandon, Fuller, C. David, Beadle, Beth M., Garden, Adam S., Rosenthal, David I., Kies, Merrill S., Papadimitrakopoulou, Vassiliki, Lai, Stephen Y., Gross, Neil D., Schwartz, David L., and Hutcheson, Katherine A.

Published
2017
Full Text
View/download PDF

12. Data from The BATTLE Trial: Personalizing Therapy for Lung Cancer

Author

Kim, Edward S., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Lee, J. Jack, primary, Blumenschein, George R., primary, Tsao, Anne, primary, Stewart, David J., primary, Hicks, Marshall E., primary, Erasmus, Jeremy, primary, Gupta, Sanjay, primary, Alden, Christine M., primary, Liu, Suyu, primary, Tang, Ximing, primary, Khuri, Fadlo R., primary, Tran, Hai T., primary, Johnson, Bruce E., primary, Heymach, John V., primary, Mao, Li, primary, Fossella, Frank, primary, Kies, Merrill S., primary, Papadimitrakopoulou, Vassiliki, primary, Davis, Suzanne E., primary, Lippman, Scott M., primary, and Hong, Waun K., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Tables 1-3 and Table A-1, Figure 1, Appendix and Information from The BATTLE Trial: Personalizing Therapy for Lung Cancer

Author

Kim, Edward S., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Lee, J. Jack, primary, Blumenschein, George R., primary, Tsao, Anne, primary, Stewart, David J., primary, Hicks, Marshall E., primary, Erasmus, Jeremy, primary, Gupta, Sanjay, primary, Alden, Christine M., primary, Liu, Suyu, primary, Tang, Ximing, primary, Khuri, Fadlo R., primary, Tran, Hai T., primary, Johnson, Bruce E., primary, Heymach, John V., primary, Mao, Li, primary, Fossella, Frank, primary, Kies, Merrill S., primary, Papadimitrakopoulou, Vassiliki, primary, Davis, Suzanne E., primary, Lippman, Scott M., primary, and Hong, Waun K., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figures S1-S8 from Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations

Author

Mitani, Yoshitsugu, primary, Liu, Bin, primary, Rao, Pulivarthi H., primary, Borra, Vishnupriya J., primary, Zafereo, Mark, primary, Weber, Randal S., primary, Kies, Merrill, primary, Lozano, Guillermina, primary, Futreal, P. Andrew, primary, Caulin, Carlos, primary, and El-Naggar, Adel K., primary

Published
2023
Full Text
View/download PDF

15. Data Supplement from Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Author

Blumenschein, George R., primary, Saintigny, Pierre, primary, Liu, Suyu, primary, Kim, Edward S., primary, Tsao, Anne S., primary, Herbst, Roy S., primary, Alden, Christine, primary, Lee, J. Jack, primary, Tang, Ximing, primary, Stewart, David J., primary, Kies, Merrill S., primary, Fossella, Frank V., primary, Tran, Hai T., primary, Mao, L., primary, Hicks, Marshall E., primary, Erasmus, Jeremy, primary, Gupta, Sanjay, primary, Girard, Luc, primary, Peyton, Michael, primary, Diao, Lixia, primary, Wang, Jing, primary, Davis, Suzanne E., primary, Minna, John D., primary, Wistuba, Ignacio, primary, Hong, Waun K., primary, Heymach, John V., primary, and Lippman, Scott M., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data from Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment

Author

Garrido-Laguna, Ignacio, primary, Janku, Filip, primary, Falchook, Gerald S., primary, Fu, Siqing, primary, Hong, David S., primary, Naing, Aung, primary, Aaron, Joanne, primary, Wang, Xuemei, primary, Kies, Merrill, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure from Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection

Author

Le, Xiuning, primary, Gleber-Netto, Frederico O., primary, Rubin, M. Laura, primary, Qing, Yun, primary, Du, Robyn, primary, Kies, Merrill, primary, Blumenschein, George, primary, Lu, Charles, primary, Johnson, Faye M., primary, Bell, Diana, primary, Lewis, Jeff, primary, Zhang, Jiexin, primary, Feng, Lei, primary, Wilson, Kaye, primary, Marcelo-Lewis, Kathrina, primary, Wang, Jing, primary, Ginsberg, Lawrence, primary, Gillison, Maura, primary, Lee, J. Jack, primary, Meric-Berstam, Funda, primary, Mills, Gordon B., primary, Myers, Jeffrey N., primary, and Pickering, Curtis R., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Tables 1 - 3 from Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications

Author

Mitani, Yoshitsugu, primary, Rao, Pulivarthi H., primary, Maity, Sankar N., primary, Lee, Yu-Chen, primary, Ferrarotto, Renata, primary, Post, Julian C., primary, Licitra, Lisa, primary, Lippman, Scott M., primary, Kies, Merrill S., primary, Weber, Randal S., primary, Caulin, Carlos, primary, Lin, Sue-Hwa, primary, and El-Naggar, Adel K., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Data from Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection

Author

Le, Xiuning, primary, Gleber-Netto, Frederico O., primary, Rubin, M. Laura, primary, Qing, Yun, primary, Du, Robyn, primary, Kies, Merrill, primary, Blumenschein, George, primary, Lu, Charles, primary, Johnson, Faye M., primary, Bell, Diana, primary, Lewis, Jeff, primary, Zhang, Jiexin, primary, Feng, Lei, primary, Wilson, Kaye, primary, Marcelo-Lewis, Kathrina, primary, Wang, Jing, primary, Ginsberg, Lawrence, primary, Gillison, Maura, primary, Lee, J. Jack, primary, Meric-Berstam, Funda, primary, Mills, Gordon B., primary, Myers, Jeffrey N., primary, and Pickering, Curtis R., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figures 1 - 3 from Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications

Author

Mitani, Yoshitsugu, primary, Rao, Pulivarthi H., primary, Maity, Sankar N., primary, Lee, Yu-Chen, primary, Ferrarotto, Renata, primary, Post, Julian C., primary, Licitra, Lisa, primary, Lippman, Scott M., primary, Kies, Merrill S., primary, Weber, Randal S., primary, Caulin, Carlos, primary, Lin, Sue-Hwa, primary, and El-Naggar, Adel K., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Tables S1-S7 from Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations

Author

Mitani, Yoshitsugu, primary, Liu, Bin, primary, Rao, Pulivarthi H., primary, Borra, Vishnupriya J., primary, Zafereo, Mark, primary, Weber, Randal S., primary, Kies, Merrill, primary, Lozano, Guillermina, primary, Futreal, P. Andrew, primary, Caulin, Carlos, primary, and El-Naggar, Adel K., primary

Published
2023
Full Text
View/download PDF

24. Data from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 4 from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

26. Data from Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer

Author

Neskey, David M., primary, Osman, Abdullah A., primary, Ow, Thomas J., primary, Katsonis, Panagiotis, primary, McDonald, Thomas, primary, Hicks, Stephanie C., primary, Hsu, Teng-Kuei, primary, Pickering, Curtis R., primary, Ward, Alexandra, primary, Patel, Ameeta, primary, Yordy, John S., primary, Skinner, Heath D., primary, Giri, Uma, primary, Sano, Daisuke, primary, Story, Michael D., primary, Beadle, Beth M., primary, El-Naggar, Adel K., primary, Kies, Merrill S., primary, William, William N., primary, Caulin, Carlos, primary, Frederick, Mitchell, primary, Kimmel, Marek, primary, Myers, Jeffrey N., primary, and Lichtarge, Olivier, primary

Published
2023
Full Text
View/download PDF

27. Supplemental Table S1 from Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer

Author

Neskey, David M., primary, Osman, Abdullah A., primary, Ow, Thomas J., primary, Katsonis, Panagiotis, primary, McDonald, Thomas, primary, Hicks, Stephanie C., primary, Hsu, Teng-Kuei, primary, Pickering, Curtis R., primary, Ward, Alexandra, primary, Patel, Ameeta, primary, Yordy, John S., primary, Skinner, Heath D., primary, Giri, Uma, primary, Sano, Daisuke, primary, Story, Michael D., primary, Beadle, Beth M., primary, El-Naggar, Adel K., primary, Kies, Merrill S., primary, William, William N., primary, Caulin, Carlos, primary, Frederick, Mitchell, primary, Kimmel, Marek, primary, Myers, Jeffrey N., primary, and Lichtarge, Olivier, primary

Published
2023
Full Text
View/download PDF

28. Supplemental Methods from Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer

Author

Neskey, David M., primary, Osman, Abdullah A., primary, Ow, Thomas J., primary, Katsonis, Panagiotis, primary, McDonald, Thomas, primary, Hicks, Stephanie C., primary, Hsu, Teng-Kuei, primary, Pickering, Curtis R., primary, Ward, Alexandra, primary, Patel, Ameeta, primary, Yordy, John S., primary, Skinner, Heath D., primary, Giri, Uma, primary, Sano, Daisuke, primary, Story, Michael D., primary, Beadle, Beth M., primary, El-Naggar, Adel K., primary, Kies, Merrill S., primary, William, William N., primary, Caulin, Carlos, primary, Frederick, Mitchell, primary, Kimmel, Marek, primary, Myers, Jeffrey N., primary, and Lichtarge, Olivier, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 2 from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

30. Supplemental Figure Legends from Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer

Author

Neskey, David M., primary, Osman, Abdullah A., primary, Ow, Thomas J., primary, Katsonis, Panagiotis, primary, McDonald, Thomas, primary, Hicks, Stephanie C., primary, Hsu, Teng-Kuei, primary, Pickering, Curtis R., primary, Ward, Alexandra, primary, Patel, Ameeta, primary, Yordy, John S., primary, Skinner, Heath D., primary, Giri, Uma, primary, Sano, Daisuke, primary, Story, Michael D., primary, Beadle, Beth M., primary, El-Naggar, Adel K., primary, Kies, Merrill S., primary, William, William N., primary, Caulin, Carlos, primary, Frederick, Mitchell, primary, Kimmel, Marek, primary, Myers, Jeffrey N., primary, and Lichtarge, Olivier, primary

Published
2023
Full Text
View/download PDF

31. Supplemental Figure S1 from Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer

Author

Neskey, David M., primary, Osman, Abdullah A., primary, Ow, Thomas J., primary, Katsonis, Panagiotis, primary, McDonald, Thomas, primary, Hicks, Stephanie C., primary, Hsu, Teng-Kuei, primary, Pickering, Curtis R., primary, Ward, Alexandra, primary, Patel, Ameeta, primary, Yordy, John S., primary, Skinner, Heath D., primary, Giri, Uma, primary, Sano, Daisuke, primary, Story, Michael D., primary, Beadle, Beth M., primary, El-Naggar, Adel K., primary, Kies, Merrill S., primary, William, William N., primary, Caulin, Carlos, primary, Frederick, Mitchell, primary, Kimmel, Marek, primary, Myers, Jeffrey N., primary, and Lichtarge, Olivier, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 3 from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 1 from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

34. Methods and Materials from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 2 from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure Legends from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 3 from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 1 from Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Author

Osman, Abdullah A., primary, Neskey, David M., primary, Katsonis, Panagiotis, primary, Patel, Ameeta A., primary, Ward, Alexandra M., primary, Hsu, Teng-Kuei, primary, Hicks, Stephanie C., primary, McDonald, Thomas O., primary, Ow, Thomas J., primary, Alves, Marcus Ortega, primary, Pickering, Curtis R., primary, Skinner, Heath D., primary, Zhao, Mei, primary, Sturgis, Eric M., primary, Kies, Merrill S., primary, El-Naggar, Adel, primary, Perrone, Federica, primary, Licitra, Lisa, primary, Bossi, Paolo, primary, Kimmel, Marek, primary, Frederick, Mitchell J., primary, Lichtarge, Olivier, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

40. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis

Author

Blanchard, Pierre, Garden, Adam S., Gunn, G. Brandon, Rosenthal, David I., Morrison, William H., Hernandez, Mike, Crutison, Joseph, Lee, Jack J., Ye, Rong, Fuller, C. David, Mohamed, Abdallah S.R., Hutcheson, Kate A., Holliday, Emma B., Thaker, Nikhil G., Sturgis, Erich M., Kies, Merrill S., Zhu, X. Ronald, Mohan, Radhe, and Frank, Steven J.

Published
2016
Full Text
View/download PDF

45. Laryngeal Squamous Cell Carcinoma: Advanced Disease

Author

Franco, Ramon, Shin, Jennifer J., Netterville, James, Sultan, Babar, Wirth, Lori, Kies, Merrill S., Shin, Jennifer J., editor, Hartnick, Christopher J., editor, Randolph, Gregory W., editor, Cunningham, Michael J., editor, Kenna, Margaret, editor, Willging, J. Paul, editor, Nadol, Joseph B., Jr., editor, Rauch, Steven D., editor, Piccirillo, Jay F., editor, and Johnson, Jonas T., editor

Published
2008
Full Text
View/download PDF

46. Advanced Head and Neck Malignancy

Author

Wirth, Lori, Sultan, Babar, Kies, Merrill S., Shin, Jennifer J., editor, Hartnick, Christopher J., editor, Randolph, Gregory W., editor, Cunningham, Michael J., editor, Kenna, Margaret, editor, Willging, J. Paul, editor, Nadol, Joseph B., Jr., editor, Rauch, Steven D., editor, Piccirillo, Jay F., editor, and Johnson, Jonas T., editor

Published
2008
Full Text
View/download PDF

48. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection

Author

Le, Xiuning, primary, Gleber-Netto, Frederico O., additional, Rubin, M. Laura., additional, Qing, Yun, additional, Du, Robyn, additional, Kies, Merrill, additional, Blumenschein, Jr, George, additional, Lu, Charles, additional, Johnson, Faye M., additional, Bell, Diana, additional, Lewis, Jeff, additional, Zhang, Jiexin, additional, Feng, Lei, additional, Wilson, Kaye, additional, Marcelo-Lewis, Kathrina, additional, Wang, Jing, additional, Ginsberg, Lawrence, additional, Gillison, Maura, additional, Lee, J. Jack., additional, Meric-Bernstam, Funda, additional, Mills, Gordon B., additional, William, William N., additional, Myers, Jeffrey N., additional, and Pickering, Curtis R., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results